P.3.b.002 Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome

2014 ◽  
Vol 24 ◽  
pp. S491-S492
Author(s):  
I. Popovic ◽  
D. Ravanic ◽  
V. Popovic ◽  
S. Vladejic ◽  
A. Stanojevic
Keyword(s):  
Metabolic Syndrome ◽  
Term Treatment ◽  
The Metabolic Syndrome ◽  
Long Term Treatment

scholarly journals Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome

2015 ◽  
Vol 143 (11-12) ◽  
pp. 712-718 ◽  
Author(s):  
Irena Popovic ◽  
Dragan Ravanic ◽  
Slobodan Jankovic ◽  
Dragan Milovanovic ◽  
Marko Folic ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Family History ◽  
International Diabetes Federation ◽  
Term Treatment ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Long Term Treatment ◽  
Schizophrenic Patients

Introduction. The risk of metabolic abnormalities is greatly increased in schizophrenic patients started on an atypical antipsychotic medication. Patients with psychiatric disorders exceed mortality ranges resulting from, among others, increased risk of cardiovascular events. Other factors contributing to the development of metabolic syndrome include prolonged duration of illness, increasing age, female sex and lifestyle factors. Objective. This cross-sectional study was taken up to assess the prevalence of the metabolic syndrome (MetS) in schizophrenic patients receiving olanzapine monotherapy for at least six months and to determine the most important risk factors associated with metabolic syndrome presence in these patients. Methods. A total of 93 long term hospitalized schizophrenic patients (71 men, 22 women), had a screening of the following: case-history data, psychiatric scales, anthropometric measures, blood (fasting glucose, lipid status, C-reactive protein - CRP) and urine samples (microalbuminuria). Results. Prevalence of MetS according to International Diabetes Federation criteria in our study was 34.4%. The multivariate analysis distinguished the following significant predictors of MetS presence (in order of appearance): data about diabetes mellitus in family history (p=0.002), body mass index >25 kg/m2 (p=0.002), hyperlipidemia in family history (p=0.008), and elevated CRP value (p=0.042). Conclusion. High rate of MetS in patients treated with olanzapine in this study exceeds MetS prevalence in general population. Among observed parameters, our study pointed to several ?high risk? predictors associated with MetS presence. Regular monitoring of cardiometabolic risk factors is highly recommended. Positive heredity distress mentioned above may direct a psychiatrist to prescribe some other drug than olanzapine in the long term treatment of schizophrenia.

scholarly journals Sildenafil citrate long-term treatment effects on cardiovascular reactivity in a SHR experimental model of metabolic syndrome

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0223914 ◽  
Author(s):  
Yosra Doghri ◽  
Fabien Chetaneau ◽  
Moez Rhimi ◽  
Aicha Kriaa ◽  
Valérie Lalanne ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Experimental Model ◽  
Cardiovascular Reactivity ◽  
Treatment Effects ◽  
Term Treatment ◽  
Sildenafil Citrate ◽  
Long Term Treatment

scholarly journals A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project

2013 ◽  
Vol 111 (4) ◽  
pp. 643-652 ◽  
Author(s):  
Rocio de la Iglesia ◽  
Patricia Lopez-Legarrea ◽  
Itziar Abete ◽  
Isabel Bondia-Pons ◽  
Santiago Navas-Carretero ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
American Heart Association ◽  
American Heart ◽  
Heart Association ◽  
Control Group ◽  
The Metabolic Syndrome ◽  
Long Term Treatment ◽  
Dietary Strategy

The long-term effects of dietary strategies designed to combat the metabolic syndrome (MetS) remain unknown. The present study evaluated the effectiveness of a new dietary strategy based on macronutrient distribution, antioxidant capacity and meal frequency (MEtabolic Syndrome REduction in NAvarra (RESMENA) diet) for the treatment of the MetS when compared with the American Heart Association guidelines, used as Control. Subjects with the MetS (fifty-two men and forty-one women, age 49 (se1) years, BMI 36·11 (se0·5) kg/m2) were randomly assigned to one of two dietary groups. After a 2-month nutritional-learning intervention period, during which a nutritional assessment was made for the participants every 15 d, a 4-month self-control period began. No significant differences were found between the groups concerning anthropometry, but only the RESMENA group exhibited a significant decrease in body weight ( − 1·7 %;P= 0·018), BMI ( − 1·7 %;P= 0·019), waist circumference ( − 1·8 %;P= 0·021), waist:hip ratio ( − 1·4 %;P= 0·035) and android fat mass ( − 6·9 %;P= 0·008). The RESMENA group exhibited a significant decrease in alanine aminotransferase and aspartate aminotransferase (AST) concentrations ( − 26·8 %;P= 0·008 and − 14·0 %;P= 0·018, respectively), while the Control group exhibited a significant increase in glucose (7·9 %;P= 0·011), AST (11·3 %;P= 0·045) and uric acid (9·0 %;P< 0·001) concentrations. LDL-cholesterol (LDL-C) concentrations were increased (Control group: 34·4 %;P< 0·001 and RESMENA group: 33·8 %;P< 0·001), but interestingly so were the LDL-C:apoB ratio (Control group: 28·7 %;P< 0·001, RESMENA group: 17·1 %;P= 0·009) and HDL-cholesterol concentrations (Control group: 21·1 %;P< 0·001, RESMENA group: 8·7;P= 0·001). Fibre was the dietary component that most contributed to the improvement of anthropometry, while body-weight loss explained changes in some biochemical markers. In conclusion, the RESMENA diet is a good long-term dietary treatment for the MetS.

Metabolic syndrome in patients with schizophrenia receiving long-term treatment with lurasidone, quetiapine XR, or risperidone

2016 ◽  
Vol 33 (S1) ◽  
pp. S105-S105
Author(s):  
J. Newcomer ◽  
M. Tocco ◽  
A. Pikalov ◽  
H. Zheng ◽  
J. Cucchiaro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Antipsychotic Agents ◽  
Term Treatment ◽  
Adult Patients ◽  
Fixed Dose ◽  
Controlled Study ◽  
Double Blind ◽  
Quetiapine Xr ◽  
Long Term Treatment

IntroductionLurasidone has demonstrated low propensity for metabolic disturbance in adult patients with schizophrenia in short-term studies.ObjectivesTo evaluate metabolic syndrome occurrence during long-term lurasidone treatment in patients with schizophrenia.AimsTo compare metabolic syndrome rates with lurasidone versus other antipsychotic agents.MethodsMetabolic syndrome rates (as defined by the US National Cholesterol Education Program-Adult Treatment Panel III) were evaluated in adult patients with schizophrenia treated with lurasidone in 2 long-term, active-controlled studies (quetiapine XR or risperidone). In the quetiapine XR-controlled study, patients completing a 6-week, double-blind, placebo-controlled, fixed-dose trial of lurasidone (74 mg/d or 148 mg/d) or quetiapine XR (600 mg/d) continued on double-blind, flexibly dosed lurasidone (37–148 mg/d) or quetiapine XR (200–800 mg/d) for up to 12 months. In the risperidone-controlled study, patients received double-blind, flexibly dosed lurasidone (37–111 mg/d) or risperidone (2–6 mg/d) for up to 12 months.ResultsAmong patients without metabolic syndrome at baseline in the quetiapine XR-controlled study, 2.4% (2/84) of lurasidone-treated patients and 7.4% (2/27) of quetiapine XR-treated patients developed metabolic syndrome at month 12 (P = NS). Of patients without metabolic syndrome at baseline in the risperidone-controlled study, 10.3% (12/117) and 23.2% (16/69) of lurasidone- and risperidone-treated patients, respectively, developed metabolic syndrome at month 12 (P = 0.02).ConclusionsLong-term treatment with lurasidone was associated with lower rates of metabolic syndrome in patients with schizophrenia compared to treatment with quetiapine XR or risperidone.SupportSunovion Pharmaceuticals Inc.ClinicalTrials.gov identifiersNCT00789698, NCT00641745.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Poster #T169 EFFECT OF LONG-TERM TREATMENT WITH LURASIDONE OR RISPERIDONE ON METABOLIC SYNDROME STATUS IN PATIENTS WITH SCHIZOPHRENIA

2014 ◽  
Vol 153 ◽  
pp. S349
Author(s):  
John W. Newcomer ◽  
Andrei Pikalov ◽  
Kei Watabe ◽  
Josephine Cucchiaro ◽  
Krithika Rajagopalan ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document